Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function

International Immunology

Volumn 20, Issue 4, 2008, Pages 591-600

  de León, Joel ^a   Fernández, Audry ^a   Clavell, Marilyn ^a   Labrada, Mayrel ^a   Bebelagua, Yanin ^a   Mesa, Circe ^a   Fernández, Luis E ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

CD4+ T cells; Dendritic cells; Immune dysfunction; NGcGM3

Indexed keywords

BETA ACTIN; CD3 ANTIGEN; CD4 ANTIGEN; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CYTOKINE; GANGLIOSIDE GM3; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; SIALIC ACID; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; LYMPHOCYTE CULTURE; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TISSUE SPECIFICITY; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; ENZYME INHIBITORS; G(M3) GANGLIOSIDE; GLUCOSYLTRANSFERASES; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; N-ACETYLNEURAMINIC ACID; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 41149148210     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn018     Document Type: Article

References (42)

1. Portoukalian, J., Zwingelstein, G. and Dore, J. F. 1979. Lipid composition of human malignant melanoma tumours at various levels of malignant growth. Eur. J. Biochem. 94:19.
2. Ritter, G. and Livingston, P. O. 1991. Ganglioside antigens expressed by human cancer cells. Semin. Cancer Biol. 6:401.
3. Wiesner, D. A. and Sweeley, C. C. 1995. Circulating gangliosides of breast-cancer patients. Int. J. Cancer 3:294.
4. Birklé, S., Zeng, G., Gao, L., Yu, R. K. and Aubry, J. 2003. Role of tumour-associated gangliosides in cancer progression. Biochimie 85:455.
5. Caldwell, S., Heitger, A., Shen, W., Liu, Y., Taylor, B. and Ladisch, S. 2003. Mechanisms of ganglioside inhibition of APC function. J. Immunol. 171:1676.
6. McKallip, R., Li, R. and Ladisch, S. 1999. Tumour gangliosides inhibit the tumour-specific immune response. J. Immunol. 163:3718.
7. Péguet-Navarro, J., Sportouch, M., Popa, I., Berthier, O., Schmitt, D. and Portoukalian, J. 2003. Gangliosides from human melanoma tumours impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170:3488.
8. Shurin, G. V., Shurin, M. R., Bykovskaia, S., Shogan, J., Lotze, M. T. and Barksdale, E. M., Jr 2001. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61:363.
9. Shen, W., Falahati, R., Stark, R., Leitenberg, D. and Ladisch, S. 2005. Modulation of CD4 Th cell differentiation by ganglioside GD1a in vitro. J. Immunol. 175:4927.
10. Chou, H. H., Takematsu, H., Diaz, S. et al. 1998. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc. Natl Acad. Sci. USA 95:11751.
11. Irie, A., Koyama, S., Kozutsumi, Y., Kawasaki, T. and Suzuki, A. 1998. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J. Biol. Chem. 273:15866.
12. Higashi, H., Sasabe, T., Fukui, Y., Maru, M. and Kato, S. 1988. Detection of gangliosides as N-glycolylneuraminic acid-specific tumour-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn. J. Cancer Res. 79:952.
13. Marquina, G., Waki, H., Fernández, L. E. et al. 1996. Gangliosides expressed in human breast cancer. Cancer Res. 56:5165.
14. Miyake, M., Hashimoto, K., Ito, M. et al. 1990. Abnormal occurrence and the differentiation dependent distribution of N acetyl and N-glycolyl species of ganglioside GM2 in human germ cell tumours. Cancer 65:499.
15. de Leon, J., Fernández, A., Mesa, C., Clavel, M. and Fernández, L. E. 2006. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: Effect over CD4 expression on T cells. Cancer Immunol. Immunother. 55:443.
16. Muthing, J., Steuer, H., Peter-Katalinic, J. et al. 1994. Expression of gangliosides GM3 (NeuAc) and GM3 (NeuGc) in myelomas and hybridomas of mouse, rat, and human origin. J. Biochem. (Tokyo). 116:64.
17. Kono, K., Kawaida, H., Takahashi, A. et al. 2006. CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 9:1064.
18. Yamaguchi, T. and Sakaguchi, S. 2006. Regulatory T cells in immune-surveillance and treatment of cancer. Semin. Cancer Biol. 2:115.
19. Gallimore, A. and Sakaguchi, S. 2002. Regulation of tumour immunity by CD25+ T cells. Immunology 1:5.
20. Oliva, J. P., Valdes, Z., Casaco, A. et al. 2006. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res. Treat. 96:115.
21. Carr, A., Rodríguez, E., Arango, M., del, C. et al. 2003. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J. Clin. Oncol. 21:1015.
22. Svennerholm, L. and Fredmand, P. 1980. A procedure for the quantitative isolation of brain gangliosides. Biochim. Biophys. Acta. 617:97.
23. Folch, P. J., Arsove, S. and Meath, J. A. 1951. Isolation of brain stradin: A new type of large molecular tissue component. J. Biol. Chem. 191:819.
24. Svennerholm, L. 1957. Quantitative estimation of sialic acid: A colorimetric resorcinol-hydrocloridric acid method. Biochim. Biophys. Acta. 24:604.
25. Carr, A., Mullet, A., Mazorra, Z. et al. 2000. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma. 19:241.
26. Lavelle, E. C., McNeela, E., Armstrong, M. E., Leavy, O., Higgins, S. C. and Mills, K. H. 2003. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J. Immunol. 171:2384.
27. Soussi, N., Milon, G., Colle, J. H., Mougneau, E., Glaichenhaus, N. and Goossens. P. L. 2000. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect. Immun. 68:1498.
28. Takahashi, T., Kuniyasu, Y., Toda, M. et al. 1998. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/ suppressive state. Int. Immunol. 10:1969.
29. Tourkova, I. L., Shurin, G. V., Chatta, G. S. et al. 2005. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J. Immunol. 175:3045.
30. Sorice, M., Pavan, A., Misasi, R. et al. 1995. Monosialoganglioside GM3 induces CD4 internalization in human peripheral blood T lymphocytes. Scand. J. Immunol. 41:148.
31. Irani, D. M. Lin, K. I. and Griffin, D. E. 1996. Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J. Immunol. 157:4333.
32. Kanda, N. 1999. Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem. Biophys. Res. Commun. 256:41.
33. Crespo, F. A., Sun, X., Cripps, J. G. and Fernandez-Botran, R. 2006. The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses. J. Leukoc. Biol. 79:586.
34. Merritt, W. D., Der-Minassian, V. and Reaman, G. H. 1994. Increased GD3 ganglioside in plasma of children with T-cell acute lymphoblastic leukemia. Leukemia. 8:816.
35. Valentino, L., Moss, T., Olson, E., Wang, H. J., Elashoff, R. and Ladisch, S. 1990. Shed tumor gangliosides and progression of human neuroblastoma. Blood. 75:1564.
36. Laguens, G., Coronato, S., Laguens, R., Portiansky, E. and Di Girolamo, V. 2002. Human regional lymph nodes draining cancer exhibit a profound dendritic cell depletion as comparing to those from patients without malignancies. Immunol. Lett. 84:159.
37. Holbrook, E. K., Nouri, N., Nowels, K., Johnson, D., Holmes, S. and Lee, P. P. 2005. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2:904.
38. Bennaceur, K., Popa, I., Portoukalian, J., Berthier-Vergnes, O. and Peguet-Navarro, J. 2006. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int. Immunol. 18:879.
39. Cochran, A. J., Huang, R. R., Lee, J., Itakura, E., Leong, S. P. and Essner, R. 2006. Tumour-induced immune modulation of sentinel lymph nodes. Nat. Rev. Immunol. 6:659.
40. Shu, S., Cochran, A. J., Huang, R. R., Morton, D. L. and Maecker, H. T. 2006. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev. 25:233.
41. Valzasina, B., Piconese, S., Guiducci, C. and Colombo, M. P. 2006. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 8:4488.
42. Alfonso, M., Diaz, A., Hernandez, A. M., Perez, A. et al. 2002. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol. 168:2523.